- Home
- MHUA vs EVAX Comparison
MHUA vs EVAX Comparison
Compare MHUA & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHUA
- EVAX
- Stock Information
- Founded
- MHUA 1990
- EVAX 2008
- Country
- MHUA China
- EVAX Denmark
- Employees
- MHUA N/A
- EVAX N/A
- Industry
- MHUA Medical Specialities
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MHUA Health Care
- EVAX Health Care
- Exchange
- MHUA Nasdaq
- EVAX Nasdaq
- Market Cap
- MHUA 12.8M
- EVAX 14.3M
- IPO Year
- MHUA 2022
- EVAX 2021
- Fundamental
- Price
- MHUA $0.50
- EVAX $1.65
- Analyst Decision
- MHUA
- EVAX Strong Buy
- Analyst Count
- MHUA 0
- EVAX 2
- Target Price
- MHUA N/A
- EVAX $11.00
- AVG Volume (30 Days)
- MHUA 1.0M
- EVAX 27.9K
- Earning Date
- MHUA 11-22-2024
- EVAX 10-31-2024
- Dividend Yield
- MHUA N/A
- EVAX N/A
- EPS Growth
- MHUA 29.93
- EVAX N/A
- EPS
- MHUA 0.37
- EVAX N/A
- Revenue
- MHUA $94,252,537.00
- EVAX $3,295,000.00
- Revenue This Year
- MHUA N/A
- EVAX $4,845.21
- Revenue Next Year
- MHUA N/A
- EVAX $30.30
- P/E Ratio
- MHUA $1.41
- EVAX N/A
- Revenue Growth
- MHUA N/A
- EVAX N/A
- 52 Week Low
- MHUA $0.45
- EVAX $1.59
- 52 Week High
- MHUA $2.81
- EVAX $13.61
- Technical
- Relative Strength Index (RSI)
- MHUA 32.99
- EVAX 20.33
- Support Level
- MHUA $0.45
- EVAX $1.59
- Resistance Level
- MHUA $0.53
- EVAX $2.63
- Average True Range (ATR)
- MHUA 0.06
- EVAX 0.22
- MACD
- MHUA -0.01
- EVAX -0.10
- Stochastic Oscillator
- MHUA 12.99
- EVAX 3.97
About MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.